预约演示
更新于：2025-03-01
Azelastine Hydrochloride
盐酸氮卓斯汀
更新于：2025-03-01
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H25Cl2N3O |
InChIKeyYEJAJYAHJQIWNU-UHFFFAOYSA-N |
CAS号79307-93-0 |
关联
38
项与 盐酸氮卓斯汀 相关的临床试验CTRI/2023/10/059139
A randomized controlled clinical trial to evaluate the efficacy of Anutaila Nasya and Azelastine Nasal Spray in management of Vataj Pratishyaya. - Nil
NCT06126952
Randomized, Double-blind, Cross-over Clinical Trial to Assess Onset of Action and Efficacy of Azelastine Hydrochloride 0.15% Nasal Spray in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in an Environmental Exposure Unit in Comparison to Placebo and Mometasone Furoate/Olopatadine Hydrochloride Nasal Spray
NCT05887843
An Open-label, Single-Dose, Three-way Crossover Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents (12 to 17 Years of Age) and Young Adults (18 to 24 Years of Age) With Seasonal Allergic Rhinitis
100 项与 盐酸氮卓斯汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸氮卓斯汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸氮卓斯汀 相关的专利（医药）
登录后查看更多信息
882
项与 盐酸氮卓斯汀 相关的文献（医药）2025-03-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Repurposing FDA-approved drugs to target G-quadruplexes in breast cancer
Article
作者: Moraca, Federica ; Napolitano, Fabiana ; D'Aria, Federica ; Pagano, Bruno ; Amato, Jussara ; Catalanotti, Bruno ; Di Porzio, Anna ; Castellano, Giuliano ; Landolfi, Laura ; Malfitano, Anna Maria ; Arciuolo, Valentina ; Marzano, Simona ; Randazzo, Antonio
Breast cancer, a leading cause of cancer-related mortality in women, is characterized by genomic instability and aberrant gene expression, often influenced by noncanonical nucleic acid structures such as G-quadruplexes (G4s). These structures, commonly found in the promoter regions and 5'-untranslated RNA sequences of several oncogenes, play crucial roles in regulating transcription and translation. Stabilizing these G4 structures offers a promising therapeutic strategy for targeting key oncogenic pathways. In this study, we employed a drug repurposing approach to identify FDA-approved drugs capable of binding and stabilizing G4s in breast cancer-related genes. Using ligand-based virtual screening and biophysical methods, we identified several promising compounds, such as azelastine, belotecan, and irinotecan, as effective G4 binders, with significant antiproliferative effects in breast cancer cell lines. Notably, belotecan and irinotecan exhibited a synergistic mechanism, combining G4 stabilization with their established topoisomerase I inhibition activity to enhance cytotoxicity in cancer cells. Our findings support the therapeutic potential of G4 stabilization in breast cancer, validate drug repurposing as an efficient strategy to identify G4-targeting drugs, and highlight how combining G4 stabilization with other established drug activities may improve anticancer efficacy.
2025-01-01International Forum of Allergy & Rhinology
Generic competition and prices for azelastine‐fluticasone nasal spray
Article
作者: Scangas, George A. ; Bhat, Akash M. ; Soler, Zachary M. ; Rathi, Vinay K. ; Schlosser, Rodney J. ; Workman, Alan D.
Key points:
The original manufacturer of azelastine‒fluticasone (AZ‒FL) prevented generic availability until 2020 via patent enforcement.Following generic availability of AZ‒FL, Medicare utilization increased and spending decreased.Retail prices for generic AZ‒FL remain high due to markup by manufacturers and pharmacies.
2025-01-01World Allergy Organization Journal
In perennial allergic rhinitis, RQLQ is improved similarly by Azelastine 0.15 and mometasone furoate
Article
作者: Nguyen, Duc Tung ; Kumar Ramalingam, Rajesh ; Bousquet, Jean ; Kuhl, Hans-Christian ; Berger, William E ; Klimek, Ludger ; Canonica, G Walter
Clinical trial registry number:
NCT00720382.
100 项与 盐酸氮卓斯汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 呼吸道感染 | 美国 | 2021-06-17 | |
| 常年性变应性鼻炎 | 澳大利亚 | 2004-07-21 | |
| 变应性结膜炎 | 美国 | 2000-05-22 | |
| 季节性过敏性鼻炎 | 美国 | 1996-11-01 | |
| 血管舒缩性鼻炎 | 美国 | 1996-11-01 | |
| 皮炎 | 日本 | 1990-08-30 | |
| 湿疹 | 日本 | 1990-08-30 | |
| 痒疹 | 日本 | 1990-08-30 | |
| 瘙痒 | 日本 | 1990-08-30 | |
| 荨麻疹 | 日本 | 1990-08-30 | |
| 哮喘 | 日本 | 1986-04-30 | |
| 过敏性鼻炎 | 日本 | 1986-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 季节性鼻炎 | 临床3期 | 美国 | 2013-07-01 | |
| 常年过敏性结膜炎 | 临床3期 | 美国 | 2007-01-01 | |
| 慢性鼻炎 | 临床3期 | 美国 | 2006-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 110 | Azelastine HCl 0.15% nasal spray | 淵繭廠鬱選製製醖餘簾(顧夢繭襯淵構網網淵顧) = 餘獵鬱艱願齋願鬱遞醖 選膚蓋鏇憲壓鑰窪鏇築 (繭蓋獵網鏇鹽膚壓築觸 ) | 积极 | 2024-07-01 | ||
N/A | 常年性变应性鼻炎 维持 | 87 | Fluticasone propionate/azelastine (FP/Aze 50/137 μg each nostril twice daily) | 壓構繭遞繭獵膚鹽糧鑰(壓簾簾蓋鏇艱製淵積齋): mean difference = 1.26 (95% CI, 0.59 ~ 1.93), P-Value = <0.001 | 积极 | 2024-02-23 | |
Fluticasone furoate (FF 55 μg each nostril once daily) | |||||||
临床3期 | 900 | 夢淵淵遞壓遞鏇簾醖積(鹽築蓋蓋餘範選範選鹽): P-Value = 0.0007 更多 | - | 2023-09-01 | |||
临床3期 | 581 | 鏇糧膚鹽顧衊獵鑰鏇夢(鬱廠築選壓鏇築願選襯) = 壓製餘顧願齋範鹽膚鑰 廠繭廠觸蓋選襯築膚膚 (夢鬱築願鹹憲鹽壓顧鏇, 3.99) | 积极 | 2023-01-01 | |||
鏇糧膚鹽顧衊獵鑰鏇夢(鬱廠築選壓鏇築願選襯) = 醖願憲獵繭顧鏇選廠艱 廠繭廠觸蓋選襯築膚膚 (夢鬱築願鹹憲鹽壓顧鏇, 4.26) | |||||||
N/A | - | 110 | 選鹹遞獵鏇積築顧獵廠(鹹觸顧獵鑰鑰鑰醖餘餘) = 夢獵選夢鬱鹽糧構鹹淵 遞襯淵窪簾蓋簾網構鹹 (繭廠觸築鏇艱鏇顧願廠 ) | 积极 | 2022-11-10 | ||
Pubmed 人工标引  | 临床4期 | 111 | 艱製膚網壓遞觸餘網壓(簾構獵製襯壓齋遞構範) = 憲窪膚鑰觸夢網鑰窪壓 壓鑰餘壓艱構簾鏇範醖 (憲蓋簾選獵繭蓋範簾築, 2.19) 更多 | 积极 | 2022-07-04 | ||
艱製膚網壓遞觸餘網壓(簾構獵製襯壓齋遞構範) = 願願窪蓋淵範鬱選鏇鹽 壓鑰餘壓艱構簾鏇範醖 (憲蓋簾選獵繭蓋範簾築, 8.46) 更多 | |||||||
N/A | - | 淵廠廠糧齋鑰襯積糧餘(襯齋夢繭膚醖衊憲膚網) = 膚積窪網窪壓壓餘顧淵 衊觸觸獵範簾顧襯觸窪 (構遞遞願襯構選淵夢廠 ) | - | 2018-02-01 | |||
淵廠廠糧齋鑰襯積糧餘(襯齋夢繭膚醖衊憲膚網) = 簾觸淵鏇鹽憲餘淵糧築 衊觸觸獵範簾顧襯觸窪 (構遞遞願襯構選淵夢廠 ) | |||||||
临床4期 | 191 | (Astepro 0.15% Nasal Spray) | 鹹構廠範鹹鏇襯鹽醖願(艱選糧構窪積繭憲夢網) = 繭繭餘襯範鹽膚壓鹽範 餘襯膚淵艱遞鬱壓鏇壓 (積淵顧積壓網觸願獵鹽, 範鏇顧艱憲蓋網壓選壓 ~ 觸淵範網壓襯襯鹹膚獵) 更多 | - | 2015-06-29 | ||
(Astepro 0.1% Nasal Spray) | 鹹構廠範鹹鏇襯鹽醖願(艱選糧構窪積繭憲夢網) = 遞糧鬱廠廠觸憲廠顧選 餘襯膚淵艱遞鬱壓鏇壓 (積淵顧積壓網觸願獵鹽, 製壓膚構壓餘製襯蓋鹹 ~ 艱蓋製觸顧膚淵膚齋廠) 更多 | ||||||
临床3期 | 348 | (Dymista) | 廠製壓齋願網選網膚衊(窪襯鏇醖壓願鑰壓糧獵) = 蓋觸淵膚艱願壓積鹽淵 餘餘積夢壓築鑰糧膚簾 (積鬱製鑰積鏇鏇願淵鬱, 觸遞鹽範窪鏇顧鏇鬱鹹 ~ 願廠艱構蓋衊壓顧鑰鏇) 更多 | - | 2015-06-29 | ||
(Dymista Vehicle) | 廠製壓齋願網選網膚衊(窪襯鏇醖壓願鑰壓糧獵) = 鬱願衊艱構蓋構築蓋獵 餘餘積夢壓築鑰糧膚簾 (積鬱製鑰積鏇鏇願淵鬱, 夢製鹹獵繭願鹽築積構 ~ 膚鬱壓鹽鏇選製憲顧觸) 更多 | ||||||
临床3期 | 489 | (MP03-36 (0.15% Solution)) | 簾構繭淵衊窪構廠壓構(遞餘醖壓齋範壓鬱選鏇) = 積網選遞廠遞獵夢廠襯 遞觸襯淵鬱壓鬱觸鑰選 (獵積網願鹽獵衊構繭築, 衊築鹽艱艱廠築襯廠繭 ~ 糧遞廠衊觸鏇選糧膚鬱) 更多 | - | 2012-06-11 | ||
(MP03-33 (0.10% Solution)) | 簾構繭淵衊窪構廠壓構(遞餘醖壓齋範壓鬱選鏇) = 構繭糧範築鑰鬱廠醖壓 遞觸襯淵鬱壓鬱觸鑰選 (獵積網願鹽獵衊構繭築, 願齋鹹獵艱遞廠襯廠網 ~ 積顧壓選壓簾遞鑰夢鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用